(Q35638378)

9 August 2017

1 reference

title

Chronic graft-versus-host disease: where do we go from here? (English)

1 reference

9 August 2017

Farag SS

1

1 reference

PubMed ID

14743199

9 August 2017

language of work or name

English

0 references

publication date

1 March 2004

1 reference

Bone Marrow Transplantation

9 August 2017

1 reference

9 August 2017

33

1 reference

9 August 2017

569-577

1 reference

9 August 2017

6

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1704410

9 August 2017

0 references

cites work

Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Chronic graft-versus-host disease: clinical manifestation and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

How I treat chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Chronic graft versus host disease: a syndrome of disordered immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Chronic graft-versus-host disease after allogeneic blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Development of a prognostic model for grading chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Performance of a new clinical grading system for chronic graft-versus-host disease: a multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Pathophysiology and treatment of graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Clinical importance of confirming or excluding the diagnosis of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Amelioration of steroid-resistant chronic graft-versus-host-mediated liver disease via tacrolimus treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Thalidomide in cancer: potential uses and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

The use of thalidomide in chronic refractory graft versus host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Immune suppression by lysosomotropic amines and cyclosporine on T-cell responses to minor and major histocompatibility antigens: does synergy exist?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Hydroxychloroquine for the treatment of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Clofazimine in the treatment of annular lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Chronic graft-versus-host disease treated with UVB phototherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Immunosuppressive effects of pentostatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Graft-versus-host disease (GVHD)-specific survival and duration of systemic immunosuppressive treatment in patients who developed chronic GVHD following allogeneic haematopoietic cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Outcomes among 562 recipients of placental-blood transplants from unrelated donors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Acute and chronic graft versus host disease: histopathological evidence for two distinct pathogenetic mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. The Acute Leukemia Working Party of the European Group for Blood and Marrow

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Simultaneous use of tacrolimus and mycophenolate mofetil in combined pancreas-kidney transplant recipients: a multi-center report. The FK/MMF Multi-Center Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Salvage therapy for refractory chronic graft-versus-host disease with mycophenolate mofetil and tacrolimus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Thalidomide for the treatment of chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

The role of thalidomide in the treatment of refractory chronic graft-versus-host disease following bone marrow transplantation in children

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Response to thalidomide therapy in refractory chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Clofazimine in dermatitis ulcerosa (pyoderma gangrenosum). Open clinical trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Roferon-A in combination with Tigason in cutaneous T-cell lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

8-Methoxypsoralen and ultraviolet A therapy for cutaneous manifestations of graft-versus-host disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Treatment of oral chronic graft-versus-host disease with PUVA therapy: case report and literature review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Identification of amplified clonal T cell populations in the blood of patients with chronic graft-versus-host disease: positive correlation with response to photopheresis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Kinetics of Recovery of CD4+ T Cells in Peripheral Blood of Deoxycoformycin-Treated Patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1704410

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1704410

1 reference

9 August 2017

1 reference

PubMed ID

14743199